Glenmark launches lower cost alternative to Banzel Tablets in US
Mumbai: Drugmaker, Glenmark Pharmaceuticals Limited, today announced that the company has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel Tablets, 200 mg and 400 mg of Eisai, Inc.
Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on May 16, 2016.
Commenting on the launch, Sanjeev Krishan, President, Glenmark North America said, "We are very pleased to be one of the first generic companies in the US to offer lower cost alternative to Banzel Tablets, 200 mg and 400 mg. The launch is our commitment to provide quality and affordable healthcare to our markets for patients."
According to IQVIA sales data for the 12 month period ending April 2021, the Banzel Tablets, 200 mg and 400 mg market achieved annual sales of approximately $285.3 million*.
Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the USFDA.
Read also: Glenmark net profit up 6 percent at Rs 234 crore in Q4
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.